Dr. Jundong Li is an experienced gynecological oncologist and vice director of Gynecological Oncology Department. He is also an executive board member of Gynaecologic Oncology Committee, Guangdong Anti-cancer Association, Member of Guangdong GOG, member of Guangzhou Women and Children Healthcare Committee, as well as supervisor of postgraduate students.

Dr. Li obtained his Bachelor degree and Master degree in Sun Yat-sen University in 1991 and 1999, respectively. He has been practicing as a gynecological oncologist for 23 years and has extensive experience in diagnosis and treatment of various types of gynecological tumors.  He has special interest in laparoscopic treatment of cervical cancer and endometrial cancer.

Last Updated on: February 2015

Diagnosis and treatment of gynecological cancer, such as ovarian cancer and cervical cancer

1996-1999: Master's degree student, former Sun Yat-sen University of Medical Sciences

07/2002-09/2002: Studied laparoscopic diagnosis and treatment techniques at the Department of Obstetrics & Gynecology of the First Affiliated Hospital, Sun Yat-sen University and the Department of Obstetrics & Gynecology of the First People's Hospital of Foshan.

07/2004-12/2002: Sought further study at Department of Obstetrics & Gynecology of Queen Mary Hospital

Prof. Li graduated from Department of Medicine, former Sun Yat-sen University of Medical Sciences and was conferred upon the degree of Bachelor of Medicine in July 1986; graduated from former Tongji Medical University and was conferred upon the degree of Master of Medicine in July 1989. After her graduation in July 1989, she has been working at Gynecological Cancer at Sun Yat-sen University Cancer Center, engaging herself in clinical treatment of gynecological caner. In December 1995, she went to Queen Mary Hospital for a short-term study. In February 1998, she went to Prince of Wales Hospital, the Chinese University of Hong Kong for a six-month study. In 2004, she went to the First Affiliated Hospital, Sun Yat-sen University and the First People's Hospital of Foshan to study laparoscopic surgery. From May 2005 to June 2007, she went to the top 1 cancer hospital of America regarding comprehensive strength: MD Anderson Cancer Center for post-doctoral training on gynecology, studying and working there for about two years. After that, she came back to China, continues on clinical work of gynecological cancer.

She has published more than 60 papers, several of which are published on SCI journals, participated in compilation of several academic monographes, and led 5 research programs of provincial level, city level, departmental level and the Hospital. She serves as member of Chinese Anti-cancer Association, Gynecology Branch of Chinese Medical Association and International Gynecologic Cancer Society; expert committee member of cervical cancer prevention and treatment and associate chief committee member of Guangdong Female Medical Doctor Association; member of Gynecological Cancer Specialized Committee of Guangdong Anti-cancer Association; member of Gynecological Cancer Specialized Committee of Guangdong Health Management Association; member of scientific and technological expert library of Science and Information Technology of Guangzhou; member of medical malpractice appraisal library of Guangzhou; and member of surgical expert team of Ethics Committee of the Center. She is also one of the assessment experts of the Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry and China Postdoctoral Science Foundation, as well as review of International Journal of Gynecological Cancer, Chinese Journal of Cancer and Chinese Journal of Clinicians (Electronic Edition).

She graduated from Department of Medicine, former Sun Yat-sen University of Medical Sciences and was conferred upon the degree of Bachelor of Medicine in July 1986; graduated from former Tongji Medical University and was conferred upon the degree of Master of Medicine in July 1989. From May 2005 to June 2007, she went to MD Anderson Cancer Center for post-doctoral training on gynecology, studying and working there for about two years.

1. Li Y, Liu T, Ivan C, Huang J, Shen DY, Kavanagh JJ, et al. Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells. Front Oncol, 2013.3:58.

2. Ding W, Sun F, Li Y (Corresponding author). Clinical analysis of 106 patients with ovarian mucinus carcinoma. J of Chin Oncology, 2013, 19(2):129-132

3. Fu S, Li Y, Huang J, Liu T, Hong Z, Chen A, et al. Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3. Cancer Biol Ther, 2012.13;(11):1034.

4. Ren Y, Li Y (Corresponding author), Liu J. A modified shortened administration schedule for neoadjuvant chemotherapy with irinotecan and cisplatin in locally advanced cervical cancer. Int J Gynecol Cancer. 2011 May;21(4):685-9.

5. Li JD, Zhuang Y, Li YF, Feng YL, Hou JH, Chen L, Zhu AN, Wu QL, Yun JP. A clinicopathological aspect of primary small-cell carcinoma of the uterine cervix: a single-centre study of 25 cases. J Clin Pathol. 2011 Dec;64(12):1102-7. Epub 2011 Sep 30

6. Mo H, Li Y (Corresponding author). A Clinical analysis of 63 cases with ovarian granulose cell tumor. J Chin Oncology, 2011, 11(5): 375

7. Ren Y, Li Y (Corresponding author), He J, Liu F. The Association between the Micro一Lymphatic Vessel Density Revealed by DZ一40 and Lymph Node Metastasis of in Epithelial Ovarian Cancer. Chin Clinical Oncology, 2010, 37(17):961

8. Lan C, Li Y (Corresponding author), He J, Liu J. Placental site trophoblastic tumor: lymphatic spread and possible target markers. Gynecol Oncol. 2010 Mar;116(3):430-7

9. Lan C, Li Y (Corresponding author), Liu J. Intraperitoneal access via direct punctures is an alternative way to deliver intraperitoneal chemotherapy in ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol, 2009,114 (1):42-7

10. Cai Z, Li Y (Corresponding author), Liu F, Xu W. Study on clinicopathologicalvariables for ovarian m etastases in cervical carcinoma. Chin J Clinician (Electronic Edition), 2010, 4(10):1779

11. Li Y, Hu W, Shen DY, Kavanagh JJ, Fu S. Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis. Am J Obstet Gynecol, 2009.200; (2):177 e1.

12. Ren Y, Li Y(Corresponding author), He J, Liu F, Deng P. Expression of Ezrin and its significance in ovarian epithelial cancer. The Practical J of Cancer, 2009, 24(6): 576

13. Jaishuen A, Jimenez C, Sirisabya N, Li Y, Zheng H, Hu W, et al. Poor survival outcome with moderate and severe hypercalcemia in gynecologic malignancy patients. Int J Gynecol Cancer, 2009.19;(2):178.

14. Sirisabya N, Li Y, Jaishuen A, Zheng HG, Gershenson DM, Kavanagh JJ. Tamoxifen is safe and effective in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer, 2008.18;(4):648.

15. Deng P, Li Y(Corresponding author), He J, Liu F, Xiong Y, Ren Y. An Analysis of 23 Patients with Recurrent Ovarian Immature Teratoma. The Practical Journal of Cancer, 23(6): 650

16. Li Y, Finkel KW, Hu W, Fu S, Liu J, Coleman R, Kavanagh JJ. Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction. Gynecology Oncology, 2007, Aug; 106(2):375-80.

17. Li YF, Fu S, Hu W, Liu JH, Finkel KW, Gershenson DM, Kavanagh JJ. Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. International Journal of Gynecologic Cancer, 2007, Jul-Aug;17(4):739-63

18. Li YF, Hu W, Fu SQ, Li JD, Liu JH, Kavanagh JJ. Aromatase inhibitors in ovarian cancer: is there a role? International Journal of Gynecologic Cancer, 2007, 2007 Sep 25 [Epub ahead of print]

19. Li Y, Hu W, Fu S, Kavanagh J Proteomics in gynecologic malignancies: advances to date. American Journal of Cancer, 2006, 5(5):299-317

20. Cai Z, Li Y (Corresponding author), Liu F. Expression and Clinical Significance of uPA and PAI-1 in Epithelial Ovarian Cancer. Chinese Journal of Cancer, 2007, 26(3): 312-317

21. Li W, Li Y (Corresponding author), Feng Y, Liu F. Cervical Conization for Treatment of CIN 3 and Cervical Carcinoma StageⅠA1.Chinese J Of Oncology, 2006, 12(2): 109-111.

22. Ren Y, Li Y (Corresponding author), Liu F. Malignant Neoplasma Arising from Endometriosis: Report of 3 cases. The Practical J of Cancer, 2007, 22(6): 609-611

23. Huang Y, Li M, Liu F, Li Y, Li Y. Study of different surgeries in malignant ovarian germ cell neoplasmas. The practical J of Cancer, 2005, 20(1):75

24. Li Y, Li M. The use of paclitaxel in the treatment of cervical and endometrial cancer. The Chinese Practical J Obstetric and Gynecology, 2004, 20(3): 139-141

25. Li Y, Li M. Ovarian Metastasis and Ovarian Preservation in Cervical Cancer Patients. Chinese Journal of Modern Operative Surgery, 2004, 8(1): 60-63

26. Li Y, Li M, Liu F, Liu J, Li J. How t o Inerease the Optimal Rate of Seeondary Cytoreduetive Surgery in Reeurrent Epithelial ovarian Caneer. Chin J Cancer, 2003, 22(11)1193-1196

27. Li Y, Li M, Liu F. Oxaliplatin in the treatment of epithelial ovarian cancer. The Progress of Oncology, 2003, 1(1): 50-52

28. Li Y, Li M, Liu F, Liu J, Li J, Huang Y. The treatment of refractory epithelial ovarian cancer with single agent paclitaxel, Chin J Cancer, 2001, 20(4): 433-434

29. Li Y, Li M, Wu Q, Liu F, Li J, Zou J, Huang Y. Clinical analysis of 57 patients with ovarian dysgerminoma, Chin J Cancer , 2002, 21(1), 79-82

30. Huang Y, L i M, Liu F Li Y. Analysis of clinical efficacy of treatment for 179 geriatric patients with stage Ⅰor Ⅱ cervical cancer. Chin J Cancer , 2002, 21(11), 1238-1240

31. Li Y, Li M, Liu F. Clinical Analysis of 57 ovarian cancer patients treated with paclitaxel. Chinese J Of Oncology, 2001, 7(4): 225-22732. Li Y, Li M. Chemotherapy of ovarian sexual cord tumor. J Practical Oncology, 2002, 17(1): 6-7

33. Li Y, Li M. Etiologic progress of vulva intraepithelial neoplasia and vulva cancer. Zhong Guo Shi Yong Fu Ke Yu Chan Ke Za Zhi, 2001, 17(11): 647-648

34. Li Y, Li M. Hypersensitivity to carboplatin and cisplatin after intraperitoneal use. Chin J Obstet Gynecol, 2001,

36(10): 61735. Li Y, Li M, Li J, Liu F, Liu J. Study of recurrent characteristics of epithelial Ovarian cancer. Chin J Cancer, 2000, 19(6): 600-602.36. Li Y, Li M. Allergic Shock caused by carboplatin. Chin J Obstet Gynecol, 2000, 35(7): 398.

37. Li Y, Li M. Diagnosis and treatment of acute abdomen caused by ovarian tumor. Zhong Guo Shi Yong Fu Ke Yu Chan Ke Za Zhi, 1999, 15(8): 453－454.

38. Li Y, Li M, Wu Q. Clinical Analysis of 25 Cases of Primary Vaginal Malignant Melanoma, Chin J Obstet Gynecol ,1999, 34(3): 162-164.

39. Li Y, Li M. Relationship between serum CA125, CA199 and prognosis of patients with endometrial carcinoma. Chin J Obstet Gynecol, 1998, 33(6): 376-377

40. Li Y, Li M. Supportive treatment in patients with serious toxicity of chemotherapy. Zhong Guo Shi Yong Fu Ke Yu Chan Ke Za Zhi, 1997, 13(1): 5-6.

41. Li Y, Li M. Appendix metastasis of ovarian cancer. Zhong Guo Shi Yong Fu Ke Yu Chan Ke Za Zhi, 1995, 11(6): 349-350.

42. Li Y, Li M, Wu Q. Analysis of Clinical characteristics of patients with peritoneal mesothelioma. Chin J Obstet Gynecol, 1994, 29(11): 664-666

43. Li Y, Gu M. SCE frequency change and its clinical significance of white blood cells in patients with ovarian cancer after chemotherapy. Chin J Cancer, 1992, 11(2): 104-106.

44. Li Y, Gu M. SCE frequency and cell cycle change of lymphocytes in patients with ovarian malignancies. Tong Ji Yi Ke Da Xue Xue Bao, 1991, 20(5): 337-339

Last updated on: 2013

From 1997 to 2006, Dr Liu had been a vice chief of GO department and then since 2006, has become the director of this department. She had also been in charge of the administration of science research appointed as a vice-president of Sun Yat-sen University Cancer Center (SYSUCC) and a director of Clinical Study Center between 2004 and 2008. It was her responsibility for the establishment of Hospital Information System that gained her national prestige.

Dr Liu is an executive board member in Chinese Society of Gynecological Oncology and Gynecologic Oncology Committee of Chinese Anti-cancer Association; head of Guangdong GOG, vice president of Obstetrics and Gynecology sub-association, Guangdong Medical Association; president of Gynecologic Oncology Committee, Guangdong Anti-cancer Association.

In addition, Dr Liu is a reviewer or editorial board member for several academic Journals, including International Journal of Gynecologic Cancer, Chinese Journal of Cancer, Chinese Journal of Obstetrics and Gynecology, Chinese Journal of Medicine and so on. Dr Liu has been a practicing gynecological oncologist in SYSUCC for 30 years. In her general practice, she also actively initiated and participated in a number of clinical trials (national and international multi-center studies) and translational researches. 

human papillomavirus infection; 

molecular phenotype of ovarian carcinoma; 

chemo-resistance; 

lymph node metastasis of gynecological malignancies.

1984 1994 MD. Bacheler, Sun Yat-sen University of Medical Sciences, China.

1993 MSc. Master, Sun Yat-sen University of Medical Sciences, China.

2004 PhD, The University of Sydney, Australia

1. Shi Y, Li L, Hu Z, Li S, Wang S, Liu J (co-first author), etc. A genome-wide association study identifies two new cervical cancer susceptibility loci at 4q12 and 17q12. Nature Genetics. 2013; 45(8):918-22.

2. Huang H, Li YJ, Lan CY, Huang QD, Feng YL, Huang YW, Liu JH（*）. Clinical significance of ascites in epithelial ovarian cancer. Neoplasma. 2013; 60(5):546-52.

3. Lan C, Huang X, Cao X, Huang H, Feng Y, Huang Y, Liu J（*）. Adjuvant docetaxel and carboplatin chemotherapy administered alone or with radiotherapy in a “sandwich” protocol in patients with advanced endometrial cancer: a single-institution experience. Expert Opin Pharmacother. 2013; 14(5):535-42.

4. Huang Q, Huang H, Wan T, Deng T, Liu J（*）. Clinical outcome of 31 patients with primary malignant melanoma of the vagina. J Gynecol Oncol. 2013; 24(4):330-5.

5. Lan C, Huang X, Lin S, Huang H, Cai Q, Wan T, Lu J, Liu J（*）. Expression of M2-Polarized Macrophages is Associated with Poor Prognosis for Advanced Epithelial Ovarian Cancer. Technol Cancer Res Treat. 2013; 12(3):259-67.

6. Lan C, Huang X, Lin S, Huang H, Cai Q, Lu J, Liu J（*）.High density of IL-17-producing cells is associated with improved prognosis for advanced epithelial ovarian cancer. Cell Tissue Res. 2013; 352(2):351-9.

7. Huang YW, Guan MF, Liu JH（*）, Lan CY, Wan T, Huang X. Large animal model for retroperitoneal lymphatic and lung metastasis. Mol Med Rep. 2013; 8(6): 1617-22. 

8. Li Z, Yu CP, Zhong Y, Liu TJ, Huang QD, Zhao XH, Huang H, Tu H, Jiang S, Zhang Y, Liu JH（*）& Song LB（*）. Sam68 expression and cytoplasmic localization is correlated with lymph node metastasis as well as prognosis in patients with early-stage cervical cancer. Ann Oncol. 2012; 23(3):638-46.

9. Huang YW, Zeng Z, Li S, Liu JH（*）. Differential routes of carboplatin administration influence lymphocyte apoptosis in retroperitoneal lymph nodes. Tumour Biol. 2012; 33(6):2053-9.

10. Lan C, Huang X, Lin S, Cai M, Liu J（*）. Endometrial Stromal Sarcoma Arising from Endometriosis: A Clinicopathological Study and Literature Review. Gynecol Obstet Invest 2012; 74:288-297.

11. Huang H, Li Y, Liu J（*）, Zheng M, Feng Y, Hu K, Huang Y, Huang Q. Screening and identification of biomarkers in ascites related to intrinsic chemoresistance of serous epithelial ovarian cancers. PLoS One. 2012; 7(12): e51256

12. Huang H, Liu J（*）, Li Y, Wan T, Feng Y, Li Z, Huang Q. Metastasis to deep obturator and para-aortic lymph nodes in 649 patients with cervical carcinoma. Eur J Surg Oncol. 2011; 37(11):978-83.

13. Huang X, Lan CY, Huang HQ, Zhang YN, Huang H, Cao XP, Huang YW, Guo Y, Wan T, Liu JH（*）. Neoadjuvant docetaxel combined with cisplatin and followed by radical surgery for the treatment of locally advanced (stage IB2 - IIB) cervical cancer: preliminary results of a single-institution experience. Expert Opin Pharmacother. 2011; 12(2):165-73

14. Huang L, Zheng M, Liu JH, Xiong Y, Ding H, Tang L, Wang HY. Risk factors and prognosis of IB-IIB cervical carcinoma with common iliac lymph node metastasis. Chin J Cancer. 2010; 29(4):300-306

15. Yang GF, Xie D, Liu JH, Luo JH, Li LJ, Hua WF, Wu HM, Kung HF, Zeng YX, Guan XY. Expression and amplification of eIF-5A2 in human epithelial ovarian tumors and overexpression of eJF-5A2 is a new independent predictor of outcome in patients with ovarian carcinoma. Gynecology Oncology. 2009; 112(2):314-318.

16. Liu JH, B Rose，Huang X, Liao GW, J Carter, Wu XJ, C Thompson , Comparative analysis of characteristics of women with cervical cancer in high- versus low- incidence regions. Gynecologic Oncology. 2004; 3(94):803-810

Last updated on: 2013

Dr. Xin Huang is the professor of gynecologic oncology of Sun Yat-sen University Cancer Center. Dr. Xin Huang received her Bachelor in Medicine (equivalent to MD in the US) at Sun Yat-sen University of Medical Sciences, P. R. China in 1984. She successfully completed her residency in gynecologic oncology in 1989. Following the completion of attending programs, she was promoted to be a professor in gynecologic oncology at Sun Yat-sen University Cancer Center in 1994. Her special interests include general gynecologic surgical procedures, radical pelvic surgical procedures, and chemotherapy for malignancies arising from the female reproductive tract. She is also dedicated to taking a multidisciplinary approach to provide comprehensive care that is tailored to patients with advanced and recurrent diseases. She has been an active researcher for many years, and is well published in many peer-reviewed journals.

• General gynecologic surgical procedures
• Radical pelvic surgical procedures
• Chemotherapy
• A multidisciplinary approach to individualized patient care

• Medical Education: Sun Yat-sen University of Medical Sciences (1979-1984)
• Residency: Sun Yat-sen University Cancer Center (1984-1989)
• Attending programs: Sun Yat-sen University Cancer Center (1989-1994)

• Adjuvant docetaxel and carboplatin chemotherapy administered alone or with radiotherapy in a "sandwich" protocol in patients with advanced endometrial cancer: a single-institution experience. Expert Opin Pharmacother. 2013; 14: 535-42.

• High density of IL-17-producing cells is associated with improved prognosis for advanced epithelial ovarian cancer. Cell Tissue Res. 2013; 352: 351-9.

• Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer. Technol Cancer Res Treat. 2013; 12: 259-67.

• Endometrial stromal sarcoma arising from endometriosis: a clinicopathological study and literature review. Gynecol Obstet Invest. 2012; 74: 288-97.

• Neoadjuvant docetaxel combined with cisplatin and followed by radical surgery for the treatment of locally advanced (stage IB2 - IIB) cervical cancer: preliminary results of a single-institution experience. Expert Opin Pharmacother. 2011; 12: 165-73.

Last Updated on: February 2015 by International Office, Sun Yat-sen University Cancer Center

Dr. Xiong Ying, associate chief physician, entered Department of Gynecological Cancer at Sun Yat-sen University Cancer Center in 1996. He served as the associate chief physician and advisor of master’s degree student in 2008. After coming back to China from Japan in 2005, he carried out the Okabayashi's radical hysterectomy, the systematic para-aortic lymphadenectomy and the resection for para-aortic tumor metastasis or recurrence by combining the foreign operation methods and techniques and on the basis of his proficient skills in conventional operations for common malignant gynecological tumors, such as cervical cancer, endometrial cancer, ovarian cancer and vulvar cancer. He has mastered the techniques of radical hysterectomy, pelvic lymphadenectomy and transvaginal hysterectomy through the learning of laparoscopic technology and transvaginal operation.

He features the following five technical advantages.
1. He took the lead in practicing the Okabayashi's radical hysterectomy (since 2005) which is characterized by the ultra-radical parametrial tissue resection and vesicocervical ligament resection and minimizes the postoperative pelvic recurrence caused by parametrial tissue residue.

2. He was the first to carry out the ultra-radical pelvic lymphadenectomy (since 2005). In China, the traditional pelvic lymphadenectomy takes the obturator nerve as the bottom boundary and usually leaves over the lymph adipose tissue at the back side of the obturator nerve, which may not lead to radical resection. Additionally, the localization and dissection of parametrial lymph nodes are not emphasized in China. The vascular skeletonization of parametrial lymph nodes can reveal the common metastasis of this group of lymph nodes (especially the solitary metastasis). The ultra-radical pelvic lymphadenectomy incorporates the dissection of the above two groups of lymph nodes into its regular operation scope to minimize the possibility of leaving over metastatic lymph nodes during operation.

3. He is skilled in the systematic para-aortic lymphadenectomy and sacral lymph node dissection (since 2005). In China, these high-risk operations which require the operator to reach a high technical level are only performed in a small number of large hospitals. But they are a regular part of the operations to treat malignant ovarian tumor and endometrial cancer, etc.

4. He is proficient in the laparoscopic radical hysterectomy and pelvic lymphadenectomy (since 2009).

5. He is adept at the nerve-sparing radical hysterectomy (since 2007) which is an improved technique based on Okabayashi's radical hysterectomy. This improved hysterectomy aims to reduce postoperative urine retention. With the innovation and practice of the above-mentioned diverse operation techniques, Xiong Ying has gradually developed his unique style of operations “extensive and radical resection, delicate and fine dissection”. These operation techniques have been widely praised by his gynecological peers through the exchange and promotion across Guangdong Province and in the neighboring provinces during the last few years.

1. Led and completed one program of Guangdong Provincial Department of Science and Technology

2. Participated in and completed three programs of Guangdong Natural Science Foundation

3. Currently involved in two programs of National Natural Science Foundation of China and one program of Guangdong Natural Science Foundation

4. Engaged in clinical work on radical operation for locally advanced malignant tumor and minimally invasive operation for benign and early malignant tumor

1996 Graduated from Sun Yat-sen University of Medical Sciences (the present North Campus of Sun Yat-sen University)

2003 Conferred upon the degree of Master’s Degree in Oncology

2004 Engaged in one-year advanced studies of gynecology at Hokkaido University in Japan with the Sasakawa Medical Scholarship granted by Ministry of Health

2013 Was conferred upon the Doctoral Degree in Oncology

1. Clinical analysis of 8 cases of vulvar Paget's disease. Chinese Journal of Cancer. 2004;23(2)

2. Expression of metastasis suppressor gene KAI1/CD82 in cervical squamous cell carcinoma and its clinical significance. Chinese Journal of Cancer. 2005;24(1)

3. Correlation of serum squamous cell carcinoma antigen with clinic-pathological features and prognosis of squamous cell carcinoma of uterine cervix. Chinese Journal of Obstetrics and Gynecology. 2007;42(1)

4. Prognostic factors for patients with FIGO stage-IB cervical squamous cell carcinoma: Does the tumor size (≤ 4 cm or > 4 cm) really matter? Chinese Journal of Clinical Oncology. 2007;4(2)

5. Prognostic factors of FIGO stage-IB cervical squamous cell carcinoma. Chinese Journal of Clinical Oncology. 2007;34(17)

6. Stratification of prognostic factors for squamous cell carcinoma of the cervix and its clinical significance. Chinese Journal of Clinical Oncology. 2007;34(18)

7. Analysis of recurrence pattern and prognosis of patients with cervical envenoms and pelvic lymph node metastasis. 2008;43(6)

8. Sentinel lymph node detection using methylene blue in patients with early stage cervical cancer. Gynecologic Oncology. 2006;106(1)

9. Clinical analysis of 12 cases of uterine carcinosarcoma. Chinese Journal of Cancer. 2008;27(5)

10. Investigation on the effect of adjuvant chemotherapy for cervical cancer patients following radical hysterectomy. China Cancer. 2002;11(10)

11. Expression of WAF1 gene in epithelial ovarian cancer tissue. Journal of Sun Yat-sen University (Medical Sciences). 2003;24(6)

12. Small cell carcinoma of uterine cervix: a single institution experience. U.S. Chinese Journal of Lymphology and Oncology. 2006;5(4)

13. Clusterin expression predicts survival of invasive cervical carcinoma patients treated with radical hysterectomy and systematic lymphadenectomy. Gynecologic Oncology. 2008;108(3)

14. Clinical characteristics and prognosis of epithelial ovarian cancer in young women. Chinese Journal of Cancer. 2008;27(9)

15. Clinical significance of combined examination of pretreatment serum CYFRA21-1 and SCCAg in cervical cancer patients. Chinese Journal of Cancer. 2009;28(1):82-86

16. Cyr61, a member of ccn (connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed) family, predicts survival of patients with endometrial cancer of endometrioid subtype. Gynecol Oncol. 2009;112(1):229-34. Epub 2008 Nov 12.

17. Xiong Y, Cao LP, Rao HL, Cai MY, Liang LZ, Liu JH. Clinical significance of peritumoral lymphatic vessel density and lymphatic vessel invasion detected by D2-40 immunostaining in FIGO Ib1-IIa squamous cell cervical cancer. Cell Tissue Res. 2012 Jun;348(3):515-22.

18. Xiong Y, Liang LZ, Cao LP, Min Z, Liu JH. Clinical effects of irinotecan hydrochloride in combination with cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer. Gynecol Oncol. 2011 Oct;123(1):99-104.

19. Xiong Y, Liu JH, Zheng M, Cao LP, Liang LZ. Use of preoperative clinicopathologic characteristics to identify patients with low-risk cervical cancer suitable for Piver class II radical hysterectomy. Int J Gynaecol Obstet. 2013 Apr 1.

20. Cao L, Huang Q, He J, Lu J, Xiong Y. Elevated expression of iASPP correlates with poor prognosis and chemoresistance/radioresistance in FIGO Ib1-IIa squamous cell cervical cancer. Cell Tissue Res. 2013 Feb 19.

21. Watari H, Michimata R, Yasuda M, Ishizu A, Tomaru U, Xiong Y, Hassan MK, Sakuragi N. High prevalence of multiple human papillomavirus infection in Japanese patients with invasive uterine cervical cancer. Pathobiology. 2011;78(4):220-6.

22. Zheng M, Huang L, Liu JH, Xiong Y, Li JD, Huang X, He L, Ren YF, Wang HY. Type II radical hysterectomy and adjuvant therapy for pelvic lymph node metastasis with stage IB-IIB cervical carcinoma: a retrospective study of 288 patients. J Surg Oncol. 2011 Oct;104(5):480-5.

23. Huang L, Zheng M, Liu JH, Xiong Y, Ding H, Tang L, Wang HY. Risk factors and prognosis of IB-IIB cervical carcinoma with common iliac lymph node metastasis. Chin J Cancer. 2010 Apr;29(4):431-5.

24. Xiong Y, Peng XP, Liang LZ, Zheng M, Li JD. Ai Zheng. Clinical significance of combined examination of pretreatment serum CYFRA21-1 and SCCAg in cervical cancer patients. 2009 Jan;28(1):64-7

25. He L, Li JD, Xiong Y, Huang X, Huang L, Lin JX, Zhou Y, Zheng M. Clinicopathological and molecular markers associated with prognosis and treatment effectiveness of endometrial stromal sarcoma: a retrospective study in China. Arch Gynecol Obstet. 2013 Aug 20.

26. Dong P, Kaneuchi M, Xiong Y, Cao L, Cai M, Liu X, Guo SW, Ju J, Jia N, Konno Y, Watari H, Hosaka M, Sudo S, Sakuragi N. Identification of KLF17 as a novel epithelial to mesenchymal transition inducer via direct activation of TWIST1 in endometrioid endometrial cancer. Carcinogenesis. 2014 Apr;35(4):760-8.

27. Konno Y, Dong P, Xiong Y, Suzuki F, Lu J, Cai M, Watari H, Mitamura T, Hosaka M, Hanley SJ, Kudo M, Sakuragi N. MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells. Oncotarget. 2014 Jul 2.

Last updated on: August, 2014 by International Office, Sun Yat-sen University Cancer Center